
        <!DOCTYPE html>
        <html>
        <head>
            <title>ULTRAGENYX PHARMACEUTICAL INC. (RARE) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">ULTRAGENYX PHARMACEUTICAL INC. (RARE)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">‚Üê Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">13</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">8</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.40</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=115adf396c0ba76bbe92d14a6efb473f99b8a6019cc4a46882f64bff3d86acc1" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-09-04</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">Get the latest Ultragenyx Pharmaceutical (RARE) updates on OI drug trials, strong Phase II...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=cf6e83346ea53aaf492eb4752779398a7cd95f7cf8c0dd7e83a2fa3f8e74887f" target="_blank" rel="noopener noreferrer">Ultragenyx to Participate at Investor Conferences in September</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-29</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=db62084252315ed57e708da92d13c872dfc85da7c0890caf5fe56b7cc10485b9" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical (RARE) Valuation Spotlight as DTX401 Gene Therapy Advances With FDA Submission</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-24</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.86
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical (RARE) just kicked off a rolling Biologics License Application submission to the FDA for its DTX401 gene therapy, setting in motion a regulatory milestone that could reshape ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=5f0f35fac32a56b5c73a670de7b5920bbb5dbb1265c7474e6ccd2d17d7fc49f4" target="_blank" rel="noopener noreferrer">Will Ultragenyx‚Äôs (RARE) Rolling FDA Submission for DTX401 Reshape Its Rare Disease Narrative?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-21</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.54
                                </span>
                            </div>
                            <div class="article-summary">Earlier this week, Ultragenyx Pharmaceutical announced it has started a rolling submission of a Biologics License Application to the FDA for DTX401, its investigational gene therapy for Glycogen Stora...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=59843dd3691e06508819eddcd68ba12fe7b4d0127c5ab93bad19a2cf8f065e2a" target="_blank" rel="noopener noreferrer">Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-21</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=36cf5a3a8a1066fe42126152f89b74816c586845dc5c74f1a28c17a226078d36" target="_blank" rel="noopener noreferrer">Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetugREDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasda...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=385ab3debdd042e853701a956e43fbcf40e801e6914b3d72f81dadb7249de89e" target="_blank" rel="noopener noreferrer">Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.48
                                </span>
                            </div>
                            <div class="article-summary">Company expects to complete BLA submission in the fourth quarter of 2025NOVATO, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the initiation o...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3b39122eb10efe9b362d93dab8b46f21d6ef5030b627bccb8c95efa4c96c48b4" target="_blank" rel="noopener noreferrer">Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.35
                                </span>
                            </div>
                            <div class="article-summary">Mereo BioPharma Group plc (NASDAQ:MREO) is one of the Best 52-Week Low Penny Stocks to Buy Now. On July 9, Mereo BioPharma Group, along with Ultragenyx Pharmaceutical Inc., announced progress in the P...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=aa819c604e4f62ba924f337b8e60fef2c6fcb8ebc0b9babdb0ac2ccc347278d4" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-08</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.15
                                </span>
                            </div>
                            <div class="article-summary">NasdaqGS:RARE 1 Year Share Price vs Fair Value Explore Ultragenyx Pharmaceutical's Fair Values from the Community and......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=fb699f9cf9909c41ee02a5d5f07acb9380a6e80799e644422803de322d0d3a42" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.78
                                </span>
                            </div>
                            <div class="article-summary">NasdaqGS:RARE 1 Year Share Price vs Fair Value Explore Ultragenyx Pharmaceutical's Fair Values from the Community and......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e8907034a17f35dae0f23a135bec5ca8fee0003e570386a33158514a17a97691" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ETCompany ParticipantsEmil D....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=da3d4ba3b7a7e0534f2df2bc28731d3f14914cd2ef34436a745a21b055acaca4" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc (RARE) reports a 13% revenue increase in Q2 2025, driven by robust product sales, despite a net loss and high operating expenses....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7617ebe77f199aa474496bd605028449a8c26e9f1a9acc352366272efc9da4d0" target="_blank" rel="noopener noreferrer">Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.77
                                </span>
                            </div>
                            <div class="article-summary">RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs....</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        